Chronic Pancreatitis Market: By Treatment (Analgesic, Artificial Digestive Enzyme, Protein Supplements, Steroids, Antibiotics, and Others), By Causes (Damaged Pancreatic Duct, Cancer, Auto-Immune Disorder, Cystic Fibrosis, Gall Stones, and Hereditary), By Diagnosis (CT Scan, Magnetic Resonance Cholangiopancreatography, Ultrasound Sonography, and Others), By Route of Administration (Oral, Parenteral), By End Users (Hospitals, Clinics, Others) and Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Chronic Pancreatitis Market was valued at USD 8.2 billion in 2022 and is poised to grow at a CAGR of 5.7% over 2023-2029. Chronic Pancreatitis is a long-standing inflammation of the pancreas that alters the organ’s normal structure and functions, has symptoms such as upper abdominal pain, nausea and vomiting, steatorrhea, weight loss, and diabetes type I, and the causes of the disease include alcoholism, autoimmune disorders, intraductal obstruction, idiopathic pancreatitis, tumors, ischemia, and others. According to the Global Burden of Disease (2017), the global estimation of incidence and mortality was 9.62 cases per 1,00,000 person-years and 0.09 deaths per 1,00,000 person-years, respectively for chronic pancreatitis. An increase in consumption of alcohol and a rise in unhealthy lifestyles will act as the growth drivers for the market. However, the high cost of treatment will have a restraining impact on the chronic pancreatitis market growth. Technological advancements and increasing healthcare expenditure are the opportunities for market expansion.

Chronic Pancreatitis Market Key Developments:
  • In Dec 2021, Kangen Pharmaceuticals completed a phase-I/II trial in pancreatitis in the USA, for NI-03.
  • In July 2023, First Wave BioPharma announced its intention to submit BLA for Adrulipase alfa to the US FDA for exocrine pancreatic insufficiency.

Chronic Pancreatitis Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

North America
Chronic Pancreatitis Market Dynamics

The increase in government initiatives and investments in R&D activities by the pharmaceutical companies for drug development are the major factors driving the market growth. For instance, in Aug 2020, CT Pharmaceutical Solutions held a meeting to add chronic pancreatitis condition to the Medical Marijuana Program for adults and for patients under 18 “whose pain is recalcitrant to standard medical management”. Thus, the increased awareness, research and development for chronic disorders will lead to the growth of the market within the forecast period, whereas, lack of skilled professionals with no proper line of treatment for the disease in the market could hamper the market growth.

Key Features of the Reports

  • The chronic pancreatitis market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Chronic Pancreatitis Market Segmentation

By Treatment
  • Analgesic
  • Artificial Digestive Enzyme
  • Protein Supplements
  • Steroids
  • Antibiotics
  • Others
By Causes
  • Damaged Pancreatic Duct
  • Cancer
  • Auto-Immune Disorder
  • Cystic Fibrosis
  • Gall Stones
  • Hereditary
  • Others
By Diagnosis
  • CT Scan
  • Magnetic Resonance Cholangiopancreatography
  • Ultrasound Sonography
  • Others
By Route of Administration
  • Oral
  • Parenteral
By End User
  • Hospitals
  • Homecare
  • Others

Frequently Asked Questions

The Chronic Pancreatitis market was valued at USD 8.2 billion in 2022 and is expected to grow at a 5.7% CAGR over the forecast period 2023 – 2029.

Technological advancements and increasing healthcare expenditure are the key opportunities for the Chronic Pancreatitis market.

An increase in consumption of alcohol and a rise in unhealthy lifestyles are the growth drivers in the Chronic Pancreatitis market.

Kangen Pharma, AzurRX BioPharma, Theraly Fibrosis, First Wave BioPharma., Pfizer Inc., Baxter, B Braun, Hoffmann-La Roche Ltd., and Merck & Co., Inc. are a few companies operating in the Chronic Pancreatitis market.

  • Kangen Pharma
  • AzurRX BioPharma
  • Theraly Fibrosis 
  • First Wave BioPharma.
  • Pfizer Inc.
  • Baxter
  • B Braun
  • Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc.
  • Sanofi